DXCM
Dexcom·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 7
Bearish signal 1
Consensus Rating "Strong Buy"
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DXCM
Dexcom, Inc.
A leader of diabetes care technology
6340 Sequence Drive, San Diego, CA 92121
Designs, develops and commercializes continuous glucose monitoring systems.
Dexcom, Inc. is a company incorporated in Delaware in May 1999. The Company is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes in patients, caregivers and clinicians around the world.
Company Financials
EPS
DXCM has released its 2026 Q2 earnings. EPS was reported at 0.7, versus the expected 0.61, beating expectations. The chart below visualizes how DXCM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DXCM has released its 2026 Q2 earnings report, with revenue of 1.31B, reflecting a YoY change of 13.08%, and net profit of 249.10M, showing a YoY change of 38.54%. The Sankey diagram below clearly presents DXCM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
